The estimated Net Worth of Felixbaker Julianbaker Bros... is at least $7.03 Milion dollars as of 3 June 2013. Felixbaker Bros owns over 2,340,314 units of Acadia Pharmaceuticals Inc stock worth over $7,030,792 and over the last 12 years Felixbaker sold ACAD stock worth over $0.
Felixbaker has made over 2 trades of the Acadia Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Felixbaker bought 2,340,314 units of ACAD stock worth $33,560,103 on 3 June 2013.
The largest trade Felixbaker's ever made was buying 2,340,314 units of Acadia Pharmaceuticals Inc stock on 3 June 2013 worth over $33,560,103. On average, Felixbaker trades about 1,444,438 units every 6 days since 2013. As of 3 June 2013 Felixbaker still owns at least 440,802 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of Felixbaker Bros stock trades at the bottom of the page.
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... a Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include: